Vedanta Biosciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

vedantabio.com

Founded Year

2010

Stage

Series D | Alive

Total Raised

$233.3M

Last Raised

$68M | 1 yr ago

About Vedanta Biosciences

Vedanta Biosciences is a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria.

Vedanta Biosciences Headquarter Location

19 Blackstone Street

Cambridge, Massachusetts, 02139,

United States

857-706-1427

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Vedanta Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Vedanta Biosciences is included in 4 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

O

Omics

275 items

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Vedanta Biosciences Patents

Vedanta Biosciences has filed 10 patents.

The 3 most popular patent topics include:

  • Bacteriology
  • Clostridia
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/31/2019

5/11/2021

Allergology, Food allergies, Immunology, Clostridia, Immune system

Grant

Application Date

10/31/2019

Grant Date

5/11/2021

Title

Related Topics

Allergology, Food allergies, Immunology, Clostridia, Immune system

Status

Grant

Latest Vedanta Biosciences News

Citing 'challenging economic environment,' PhIII-ready microbiome biotech lays off 20% of staffers

Aug 11, 2022

The market downturn isn’t just sweeping up public biotechs. Vedanta Biosciences, a developer of oral drugs derived from the human microbiome, is laying off about 20% of its staff — an unfortunately common occurrence these days. But CEO Bernat Olle took the unusual step of sharing the decision on LinkedIn and offering to connect the employees being let go with any company that’s hiring in their areas. Keep reading Endpoints with a free subscription Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free. SIGN UP LOG IN MedTech clinical trials require a unique regulatory and study design approach and so engaging a highly experienced CRO to ensure compliance and accurate data across all stages is critical to development milestones. SPONSORED August 8, 2022 06:00 AM EDT In­no­v­a­tive MedTech De­mands Spe­cial­ist Clin­i­cal Tri­al Reg­u­la­to­ry Af­fairs and De­sign Tom Avery Scientific and Medical Affairs Specialist, Medical Devices Avance Clinical is the Australian CRO for international biotechs providing world-class clinical research services with FDA-accepted data across all phases. With Avance Clinical, biotech companies can leverage Australia’s supportive clinical trials environment which includes no IND requirement plus a 43.5% Government incentive rebate on clinical spend. The CRO has been delivering clinical drug development services for international biotechs for FDA and EMA regulatory approval for the past 24 years. The company has been recognized for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award and a finalist in Informa Pharma’s Best CRO award for 2022. Read More

Vedanta Biosciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Vedanta Biosciences Rank

  • When was Vedanta Biosciences founded?

    Vedanta Biosciences was founded in 2010.

  • Where is Vedanta Biosciences's headquarters?

    Vedanta Biosciences's headquarters is located at 19 Blackstone Street, Cambridge.

  • What is Vedanta Biosciences's latest funding round?

    Vedanta Biosciences's latest funding round is Series D.

  • How much did Vedanta Biosciences raise?

    Vedanta Biosciences raised a total of $233.3M.

  • Who are the investors of Vedanta Biosciences?

    Investors of Vedanta Biosciences include SymBiosis, Rock Springs Capital, Seventure Partners, Shumway Capital, JSR Corporation and 25 more.

  • Who are Vedanta Biosciences's competitors?

    Competitors of Vedanta Biosciences include Alveolus and 1 more.

You May Also Like

SciBac Logo
SciBac

SciBac aims to target Clostridium difficile (C. diff), a potentially fatal and often recurring gastrointestinal infection. Using "Evolutionary" live biotherapeutics, it stops colonization, neutralizes toxins, and directly kills C. diff organisms. The company is also developing a single-strain inhaled biotherapeutic for patients with cystic fibrosis. That therapy aims to break down the problematic mucus in the patient's lungs, while also suppressing dangerous Pseudomonas aeruginosa bacteria.

L
LISCure Biosciences

LISCure Biosciences develops a "bacteria-mediated immunotherapy" that can treat people by itself or be used in combination with other drugs for major indications such as tumors as well as degenerative neurological, autoimmune and metabolic diseases, among others.

A
Alveolus

Alveolus develops therapeutics for lung diseases such as live biotherapeutics for Bronchopulmonary Dysplasia (BPD), Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis (IPF), and Pulmonary Arterial Hypertension (PAH).

Seres Therapeutics Logo
Seres Therapeutics

Seres Therapeutics is a clinical-stage therapeutics company developing products to treat a host of disease conditions based on scientific findings related to the human microbiome. The company is developing candidates for the treatment of infectious, metabolic, and inflammatory diseases.

Evelo Biosciences Logo
Evelo Biosciences

Evelo Biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. Monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. These new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. Monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. By finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, Evelo can improve the speed, cost and success of drug discovery and development. Evelo's platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials.

4D Pharma Logo
4D Pharma

4D Pharma (NASDAQ: LBPS) researches and develops pharmaceutical products in new live biotherapeutic areas in the United Kingdom. The Company's first-generation programs include Blautix, a treatment for irritable bowel syndrome; Thetanix, a treatment for pediatric Crohns; and Rosburix, a treatment for pediatric ulcerative colitis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.